Symbols / STOK Stock $30.08 -4.08% Stoke Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
STOK (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Ian F. Smith A.C.A., C.P.A.
Exch · Country NMS · United States
Market Cap 1.87B
Enterprise Value 1.53B
Income -169.77M
Sales 32.08M
FCF (ttm) -88.69M
Book/sh 5.98
Cash/sh 5.52
Employees 170
Insider 10d —
IPO Jun 19, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 48.34
Forward P/E -9.69
PEG —
P/S 58.40
P/B 5.03
P/C —
EV/EBITDA -8.36
EV/Sales 47.80
Quick Ratio 8.57
Current Ratio 8.99
Debt/Eq 0.87
LT Debt/Eq —
EPS (ttm) -2.86
EPS next Y -3.10
EPS Growth —
Revenue Growth -96.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA -27.24%
ROE -45.58%
ROIC —
Gross Margin 100.00%
Oper. Margin -8.58%
Profit Margin 0.00%
Shs Outstand 62.28M
Shs Float 46.96M
Insider Own 3.82%
Instit Own 117.14%
Short Float 21.76%
Short Ratio 23.08
Short Interest 13.03M
52W High 40.22
vs 52W High -25.21%
52W Low 9.09
vs 52W Low 230.91%
Beta 1.20
Impl. Vol. 87.43%
Rel Volume 0.93
Avg Volume 722.61K
Volume 673.55K
Target (mean) $45.10
Tgt Median $40.00
Tgt Low $35.00
Tgt High $60.00
# Analysts 10
Recom Strong_buy
Prev Close $31.36
Price $30.08
Change -4.08%
About

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$45.10
Mean price target
2. Current target
$30.08
Latest analyst target
3. DCF / Fair value
$-25.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$30.08
Low
$35.00
High
$60.00
Mean
$45.10

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-11 reit BTIG Buy → Buy $39
2026-03-20 main Canaccord Genuity Buy → Buy $60
2026-03-19 reit BTIG Buy → Buy $39
2026-03-18 main Wedbush Outperform → Outperform $38
2026-03-18 main Chardan Capital Buy → Buy $35
2026-03-17 main Wedbush Outperform → Outperform $38
2026-03-17 main Needham Buy → Buy $40
2026-02-24 init Wolfe Research — → Outperform $40
2026-01-12 main Wedbush Outperform → Outperform $36
2026-01-05 main Chardan Capital Buy → Buy $35
2026-01-05 main Canaccord Genuity Buy → Buy $36
2025-12-15 main HC Wainwright & Co. Buy → Buy $50
2025-11-05 main Canaccord Genuity Buy → Buy $28
2025-11-05 main Wedbush Outperform → Outperform $32
2025-11-05 reit BTIG Buy → Buy $39
2025-11-03 main JP Morgan Neutral → Neutral $25
2025-10-13 main BTIG Buy → Buy $39
2025-10-10 main Needham Buy → Buy $35
2025-08-13 main Chardan Capital Buy → Buy $24
2025-08-13 main Wedbush Outperform → Outperform $22
News
RSS: Latest STOK news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-01 TICHO BARUCH S Officer — 2,243 $32.79 $73,548
2026-04-01 TICHO BARUCH S Officer — 1,838 $32.66 $60,029
2026-03-20 ALLAN JONATHAN General Counsel — 9,293 $33.64 $313,038
2026-03-19 TICHO BARUCH S Officer — 14,311 $29.99 $456,835
2026-03-19 TICHO BARUCH S Officer — 1,365 $2.19 $2,989
2026-03-18 ALLAN JONATHAN General Counsel — 8,895 $31.28 $285,901
2026-03-18 HOITT JASON Officer — 3,712 $31.28 $119,311
2026-03-18 LEGGETT THOMAS Chief Financial Officer — 4,578 $31.28 $147,145
2026-03-13 LEVIN ARTHUR A. Director — 605 $36.80 $22,264
2026-03-13 KAYE EDWARD M Director — 61,750 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
184.42
+404.50%
36.55
+316.34%
8.78
-29.22%
12.40
Operating Revenue
184.42
+404.50%
36.55
+316.34%
8.78
-29.22%
12.40
Operating Expense
205.01
+48.64%
137.93
+11.63%
123.55
+5.82%
116.76
Research And Development
137.92
+54.74%
89.13
+8.39%
82.23
+5.65%
77.84
Selling General And Administration
67.09
+37.49%
48.79
+18.08%
41.32
+6.16%
38.92
General And Administrative Expense
67.09
+37.49%
48.79
+18.08%
41.32
+6.16%
38.92
Other Gand A
67.09
+37.49%
48.79
+18.08%
41.32
+6.16%
38.92
Total Expenses
205.01
+48.64%
137.93
+11.63%
123.55
+5.82%
116.76
Operating Income
-20.59
+79.69%
-101.37
+11.68%
-114.77
-9.98%
-104.36
Total Operating Income As Reported
-20.59
+79.69%
-101.37
+11.68%
-114.77
-9.98%
-104.36
EBITDA
-18.82
+81.03%
-99.19
+11.67%
-112.30
-9.23%
-102.81
Normalized EBITDA
-18.82
+81.03%
-99.19
+11.67%
-112.30
-9.23%
-102.81
Reconciled Depreciation
1.77
-18.70%
2.18
-11.83%
2.47
+59.70%
1.55
EBIT
-20.59
+79.69%
-101.37
+11.68%
-114.77
-9.98%
-104.36
Net Income
-6.88
+92.26%
-88.98
+15.01%
-104.70
-3.59%
-101.07
Pretax Income
-6.88
+92.26%
-88.98
+15.01%
-104.70
-3.59%
-101.07
Net Non Operating Interest Income Expense
13.76
+8.85%
12.64
+27.55%
9.91
+217.36%
3.12
Net Interest Income
13.76
+8.85%
12.64
+27.55%
9.91
+217.36%
3.12
Interest Income Non Operating
—
—
—
—
Interest Income
—
—
—
—
Other Income Expense
-0.05
+79.35%
-0.25
-248.80%
0.17
-0.60%
0.17
Other Non Operating Income Expenses
-0.05
+79.35%
-0.25
-248.80%
0.17
-0.60%
0.17
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-6.88
+92.26%
-88.98
+15.01%
-104.70
-3.59%
-101.07
Net Income From Continuing Operation Net Minority Interest
-6.88
+92.26%
-88.98
+15.01%
-104.70
-3.59%
-101.07
Net Income From Continuing And Discontinued Operation
-6.88
+92.26%
-88.98
+15.01%
-104.70
-3.59%
-101.07
Net Income Continuous Operations
-6.88
+92.26%
-88.98
+15.01%
-104.70
-3.59%
-101.07
Normalized Income
-6.88
+92.26%
-88.98
+15.01%
-104.70
-3.59%
-101.07
Net Income Common Stockholders
-6.88
+92.26%
-88.98
+15.01%
-104.70
-3.59%
-101.07
Diluted EPS
—
-1.65
+30.67%
-2.38
+8.46%
-2.60
Basic EPS
—
-1.65
+30.67%
-2.38
+8.46%
-2.60
Basic Average Shares
—
54.01
+22.76%
43.99
+13.10%
38.90
Diluted Average Shares
—
54.01
+22.76%
43.99
+13.10%
38.90
Diluted NI Availto Com Stockholders
-6.88
+92.26%
-88.98
+15.01%
-104.70
-3.59%
-101.07
Total Other Finance Cost
-13.76
-8.85%
-12.64
-27.55%
-9.91
-217.36%
-3.12
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
418.43
+54.09%
271.56
+18.92%
228.34
-10.83%
256.07
Current Assets
305.70
+31.34%
232.76
+8.09%
215.34
-11.77%
244.07
Cash Cash Equivalents And Short Term Investments
284.67
+31.25%
216.90
+7.70%
201.39
-12.28%
229.59
Cash And Cash Equivalents
84.22
-34.19%
127.98
-33.15%
191.44
+68.59%
113.56
Cash Equivalents
—
—
191.44
+68.59%
113.56
Other Short Term Investments
200.45
+125.44%
88.92
+793.45%
9.95
-91.42%
116.04
Receivables
7.91
+233.83%
2.37
+3600.00%
0.06
-89.12%
0.59
Accounts Receivable
5.94
+255.88%
1.67
—
—
Accrued Interest Receivable
1.97
+181.29%
0.70
+993.75%
0.06
-89.12%
0.59
Prepaid Assets
8.74
-21.42%
11.12
-1.79%
11.32
+3.55%
10.93
Current Deferred Assets
—
—
—
0.00
Restricted Cash
0.49
+558.67%
0.07
0.00
—
Other Current Assets
3.90
+69.57%
2.30
-10.31%
2.56
-13.33%
2.96
Total Non Current Assets
112.73
+190.56%
38.80
+198.38%
13.00
+8.39%
12.00
Net PPE
6.25
-24.32%
8.25
-33.62%
12.43
+8.80%
11.43
Gross PPE
16.39
-4.15%
17.10
-10.48%
19.11
+22.19%
15.63
Accumulated Depreciation
-10.15
-14.67%
-8.85
-32.63%
-6.67
-58.57%
-4.21
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.79
+0.00%
0.79
+5.59%
0.75
+13.08%
0.67
Construction In Progress
0.61
+412.50%
0.12
+84.62%
0.07
-85.46%
0.45
Other Properties
12.77
-7.85%
13.86
-13.35%
15.99
+26.37%
12.66
Leases
2.21
-4.98%
2.33
+1.53%
2.29
+22.87%
1.87
Investments And Advances
106.26
+256.29%
29.82
0.00
—
Other Non Current Assets
0.23
-68.52%
0.72
+26.71%
0.57
+0.00%
0.57
Total Liabilities Net Minority Interest
65.98
+55.12%
42.53
-38.16%
68.78
-3.43%
71.22
Current Liabilities
57.88
+44.49%
40.06
+29.97%
30.82
-1.83%
31.39
Payables And Accrued Expenses
27.93
+171.08%
10.30
+47.62%
6.98
-11.56%
7.89
Payables
4.94
+97.72%
2.50
+47.37%
1.70
+121.28%
0.77
Accounts Payable
4.94
+97.72%
2.50
+47.37%
1.70
+121.28%
0.77
Current Accrued Expenses
22.99
+194.56%
7.81
+47.70%
5.29
-25.83%
7.13
Pensionand Other Post Retirement Benefit Plans Current
13.97
+81.82%
7.69
+36.98%
5.61
-2.49%
5.75
Current Debt And Capital Lease Obligation
3.01
+29.50%
2.32
+12.61%
2.06
-12.59%
2.36
Current Capital Lease Obligation
3.01
+29.50%
2.32
+12.61%
2.06
-12.59%
2.36
Current Deferred Liabilities
11.90
-37.33%
18.99
+24.05%
15.31
+2.88%
14.88
Current Deferred Revenue
11.90
-37.33%
18.99
+24.05%
15.31
+2.88%
14.88
Other Current Liabilities
1.06
+40.77%
0.75
-12.14%
0.86
+68.37%
0.51
Total Non Current Liabilities Net Minority Interest
8.10
+226.96%
2.48
-93.47%
37.96
-4.69%
39.82
Non Current Deferred Liabilities
6.96
0.00
-100.00%
33.07
-10.26%
36.86
Non Current Deferred Revenue
6.96
0.00
-100.00%
33.07
-10.26%
36.86
Other Non Current Liabilities
1.14
-53.95%
2.48
-49.26%
4.88
+64.56%
2.97
Stockholders Equity
352.46
+53.90%
229.02
+43.53%
159.56
-13.68%
184.85
Common Stock Equity
352.46
+53.90%
229.02
+43.53%
159.56
-13.68%
184.85
Capital Stock
0.01
+0.00%
0.01
+0.00%
0.01
+25.00%
0.00
Common Stock
0.01
+0.00%
0.01
+0.00%
0.01
+25.00%
0.00
Share Issued
58.92
+9.05%
54.03
+17.67%
45.92
+16.43%
39.44
Ordinary Shares Number
58.92
+9.05%
54.03
+17.67%
45.92
+16.43%
39.44
Additional Paid In Capital
849.62
+18.00%
720.00
+28.24%
561.43
+16.20%
483.17
Retained Earnings
-497.71
-1.40%
-490.83
-22.14%
-401.85
-35.23%
-297.15
Gains Losses Not Affecting Retained Earnings
0.54
+459.60%
-0.15
-529.17%
-0.02
+97.96%
-1.18
Other Equity Adjustments
0.54
+459.60%
-0.15
-529.17%
-0.02
+97.96%
-1.18
Total Equity Gross Minority Interest
352.46
+53.90%
229.02
+43.53%
159.56
-13.68%
184.85
Total Capitalization
352.46
+53.90%
229.02
+43.53%
159.56
-13.68%
184.85
Working Capital
247.82
+28.61%
192.70
+4.43%
184.52
-13.24%
212.68
Invested Capital
352.46
+53.90%
229.02
+43.53%
159.56
-13.68%
184.85
Total Debt
3.01
+29.50%
2.32
+12.61%
2.06
-12.59%
2.36
Capital Lease Obligations
3.01
+29.50%
2.32
+12.61%
2.06
-12.59%
2.36
Net Tangible Assets
352.46
+53.90%
229.02
+43.53%
159.56
-13.68%
184.85
Tangible Book Value
352.46
+53.90%
229.02
+43.53%
159.56
-13.68%
184.85
Available For Sale Securities
106.26
+256.29%
29.82
—
—
Investmentin Financial Assets
106.26
+256.29%
29.82
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
45.59
+152.49%
-86.85
-7.13%
-81.07
-154.40%
-31.87
Cash Flow From Continuing Operating Activities
45.59
+152.49%
-86.85
-7.13%
-81.07
-154.40%
-31.87
Net Income From Continuing Operations
-6.88
+92.26%
-88.98
+15.01%
-104.70
-3.59%
-101.07
Depreciation Amortization Depletion
1.77
-18.70%
2.18
-11.83%
2.47
+59.70%
1.55
Depreciation
1.77
-18.70%
2.18
-11.83%
2.47
+59.70%
1.55
Depreciation And Amortization
1.77
-18.70%
2.18
-11.83%
2.47
+59.70%
1.55
Other Non Cash Items
2.41
+6.31%
2.27
+0.22%
2.26
+13.62%
1.99
Stock Based Compensation
32.24
+17.36%
27.47
+8.76%
25.26
+10.51%
22.85
Asset Impairment Charge
0.70
0.00
—
—
Operating Gains Losses
0.14
—
0.00
—
Gain Loss On Sale Of PPE
0.14
0.00
-100.00%
0.00
0.00
Change In Working Capital
16.35
+158.09%
-28.14
-366.67%
-6.03
-114.02%
43.02
Change In Receivables
-4.27
-8436.00%
-0.05
—
—
Changes In Account Receivables
-4.27
-8436.00%
-0.05
—
—
Change In Prepaid Assets
-0.55
+69.48%
-1.79
-437.62%
0.53
+110.21%
-5.18
Change In Payables And Accrued Expense
21.29
+589.41%
3.09
+196.26%
-3.21
+9.12%
-3.53
Change In Other Working Capital
-0.13
+99.56%
-29.39
-777.11%
-3.35
-106.48%
51.74
Investing Cash Flow
-186.81
-73.82%
-107.47
-201.44%
105.95
+330.91%
-45.88
Cash Flow From Continuing Investing Activities
-186.81
-73.82%
-107.47
-201.44%
105.95
+330.91%
-45.88
Net PPE Purchase And Sale
-0.67
-230.05%
-0.20
+87.44%
-1.62
+59.21%
-3.96
Purchase Of PPE
-0.67
-230.05%
-0.20
+87.44%
-1.62
+59.21%
-3.96
Capital Expenditure
-0.67
-230.05%
-0.20
+87.44%
-1.62
+59.21%
-3.96
Net Investment Purchase And Sale
-186.14
-73.52%
-107.27
-199.73%
107.56
+356.59%
-41.92
Purchase Of Investment
-322.72
-92.93%
-167.27
0.00
+100.00%
-201.32
Sale Of Investment
136.58
+127.63%
60.00
-44.22%
107.56
-32.52%
159.40
Financing Cash Flow
97.39
-25.71%
131.09
+147.31%
53.01
+14.22%
46.41
Cash Flow From Continuing Financing Activities
97.39
-25.71%
131.09
+147.31%
53.01
+14.22%
46.41
Net Common Stock Issuance
87.78
-31.87%
128.84
+147.38%
52.08
+14.86%
45.34
Proceeds From Stock Option Exercised
9.61
+326.13%
2.25
+143.41%
0.93
-12.97%
1.06
Net Other Financing Charges
—
—
—
0.00
Changes In Cash
-43.84
+30.67%
-63.23
-181.19%
77.89
+348.53%
-31.34
Beginning Cash Position
128.78
-32.93%
192.01
+68.25%
114.12
-21.54%
145.46
End Cash Position
84.94
-34.04%
128.78
-32.93%
192.01
+68.25%
114.12
Free Cash Flow
44.91
+151.59%
-87.05
-5.29%
-82.68
-130.78%
-35.83
Amortization Of Securities
-1.13
+31.00%
-1.64
-405.23%
-0.33
-54.03%
-0.21
Common Stock Issuance
87.78
-31.87%
128.84
+147.38%
52.08
+14.86%
45.34
Issuance Of Capital Stock
87.78
-31.87%
128.84
+147.38%
52.08
+14.86%
45.34
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category